GE Healthcare is going beyond just selling diagnostic imaging products in India to get involved, in part, in the distribution of care. The company will team up with a U.S. cancer healthcare operator to open cancer clinics that will rely on some of its key technology.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
Drug wholesaler AmerisourceBergen continues its global expansion with an agreement to buy nearly a 20% stake in Brazilian distributor Profarma Distribuidora de Produtos Farmacêuticos (Profarma).
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.
Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.
Sagent Pharmaceuticals passed a milestone last year when it bought out a Chinese partner and took ownership of a manufacturing plant. Now the U.S. drugmaker wants to try another first and is out shopping for some proprietary products to tuck into its portfolio.
Despite China's massive investment into modernizing its healthcare infrastructure and services, the market still has a bit of a wild-west feel that can jeopardize the reputation of med tech companies and place patient safety at risk. Xinhuanet (part of the Xinhua News Agency) reported that the country's main regulatory agency determined that 10 websites published fraudulent medical device information, including fake devices for sale.
North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.
Making drugs requires ingredients--and that is what Ranbaxy Laboratories has been struggling with since the FDA banned its key active pharmaceutical ingredient (API) plant in January
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.